{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:03:09Z","timestamp":1793163789644,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Biotechnology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.copbio.2023.103045","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T02:18:30Z","timestamp":1702520310000},"page":"103045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["Progress and challenges in the translation of cancer nanomedicines"],"prefix":"10.1016","volume":"85","author":[{"given":"Fan","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huile","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.copbio.2023.103045_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"10.1016\/j.copbio.2023.103045_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","article-title":"Challenges in nanomedicine clinical translation","volume":"10","author":"Metselaar","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.copbio.2023.103045_sbref3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.copbio.2023.103045_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/1061186X.2022.2044485","article-title":"Combination therapy based on targeted nano drug co-delivery systems for liver fibrosis treatment: a review","volume":"30","author":"Zhou","year":"2022","journal-title":"J Drug Target"},{"key":"10.1016\/j.copbio.2023.103045_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7150\/thno.79625","article-title":"Nanomaterial-based CT contrast agents and their applications in image-guided therapy","volume":"13","author":"Jiang","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.copbio.2023.103045_bib6","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.copbio.2023.103045_sbref7","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114083","article-title":"Clinical translation of nanomedicines: challenges, opportunities, and keys","volume":"181","author":"Younis","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.copbio.2023.103045_bib8","article-title":"A review of the current state of nanomedicines for targeting and treatment of cancers: achievements and future challenges","volume":"4","author":"Kermanizadeh","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.copbio.2023.103045_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2020.10.003","article-title":"Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation","volume":"329","author":"Gu","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2023.103045_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrg2775","article-title":"Synthetic biology: applications come of age","volume":"11","author":"Khalil","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.copbio.2023.103045_sbref11","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2183815","article-title":"A detailed insight of the tumor targeting using nanocarrier drug delivery system","volume":"30","author":"Batool","year":"2023","journal-title":"Drug Deliv"},{"key":"10.1016\/j.copbio.2023.103045_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122570","article-title":"Nanocarriers based novel and effective drug delivery system","volume":"632","author":"Khizar","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.copbio.2023.103045_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2023.111861","article-title":"Controllable growth of drug-encapsulated metal-organic framework (MOF) on porphyrinic MOF for PDT\/chemo-combined therapy","volume":"228","author":"Liu","year":"2023","journal-title":"Mater Des"},{"key":"10.1016\/j.copbio.2023.103045_bib14","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10311-020-01142-2","article-title":"Nanoemulsions of essential oils to improve solubility, stability and permeability: a review","volume":"19","author":"Barradas","year":"2021","journal-title":"Environ Chem Lett"},{"key":"10.1016\/j.copbio.2023.103045_bib15","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1021\/acsnano.7b01762","article-title":"Size-dependent heating of magnetic iron oxide nanoparticles","volume":"11","author":"Tong","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.copbio.2023.103045_bib16","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/acs.nanolett.8b04411","article-title":"Dynamically reversible iron oxide nanoparticle assemblies for targeted amplification of T1-weighted magnetic resonance imaging of tumors","volume":"19","author":"Li","year":"2019","journal-title":"Nano Lett"},{"key":"10.1016\/j.copbio.2023.103045_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2020.01.009","article-title":"Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain","volume":"320","author":"Israel","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2023.103045_bib18","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.7150\/thno.56482","article-title":"Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view","volume":"11","author":"Huang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.copbio.2023.103045_sbref19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100851","article-title":"Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics","volume":"32","author":"Gong","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.copbio.2023.103045_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.copbio.2023.103045_sbref21","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/D0TB00649A","article-title":"Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy","volume":"8","author":"Zhou","year":"2020","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.copbio.2023.103045_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902409","article-title":"Tumor targeting strategies of smart fluorescent nanoparticles and their applications in cancer diagnosis and treatment","volume":"31","author":"He","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2020.06.010","article-title":"A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression","volume":"325","author":"Li","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2023.103045_bib24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2174\/1389203723666220520160435","article-title":"Mitochondrial targeting peptide-based nanodelivery for cancer treatment","volume":"23","author":"Ehsan","year":"2022","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.copbio.2023.103045_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201802227","article-title":"Acid-responsive transferrin dissociation and GLUT mediated exocytosis for increased blood\u2013brain barrier transcytosis and programmed glioma targeting delivery","volume":"28","author":"Ruan","year":"2018","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.apsb.2021.12.001","article-title":"Co-delivery of photosensitizer and diclofenac through sequentially responsive bilirubin nanocarriers for combating hypoxic tumors","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.copbio.2023.103045_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202206765","article-title":"Dual-cascade responsive nanoparticles enhance pancreatic cancer therapy by eliminating tumor-resident intracellular bacteria","volume":"34","author":"Kang","year":"2022","journal-title":"Adv Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib28","article-title":"Linear chimeric triblock molecules self-assembled micelles with controllably transformable property to enhance tumor retention for chemo-photodynamic therapy of breast cancer","volume":"29","author":"Liu","year":"2019","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib29","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.apsb.2020.10.009","article-title":"GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy","volume":"10","author":"Lin","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.copbio.2023.103045_sbref30","article-title":"The role of hitchhiking in cancer therapeutics\u2014a review","volume":"5","author":"Padmakumar","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.copbio.2023.103045_bib31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.7150\/thno.24183","article-title":"\u201cAlbumin hitchhiking\u201d with an evans blue analog for cancer theranostics","volume":"8","author":"Ehlerding","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.copbio.2023.103045_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202003559","article-title":"Recent advances of cell membrane-coated nanomaterials for biomedical applications","volume":"30","author":"Liu","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcis.2021.05.135","article-title":"Cathepsin B-responsive multifunctional peptide conjugated gold nanorods for mitochondrial targeting and precise photothermal cancer therapy","volume":"601","author":"Jin","year":"2021","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.copbio.2023.103045_bib34","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.apsb.2022.11.001","article-title":"Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy","volume":"12","author":"Xu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.copbio.2023.103045_bib35","article-title":"Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment","volume":"34","author":"Liu","year":"2023","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.copbio.2023.103045_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202104645","article-title":"Self-delivered supramolecular nanomedicine with transformable shape for ferrocene-amplified photodynamic therapy of breast cancer and bone metastases","volume":"31","author":"Qin","year":"2021","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib37","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1039\/D1NR01155C","article-title":"In situ injection of dual-delivery PEG based MMP-2 sensitive hydrogels for enhanced tumor penetration and chemo-immune combination therapy","volume":"13","author":"Yan","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.copbio.2023.103045_bib38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jconrel.2022.11.044","article-title":"Bioinspired nanovehicle of furoxans-oxaliplatin improves tumoral distribution for chemo-radiotherapy","volume":"353","author":"Qian","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2023.103045_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb3116","article-title":"A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis","volume":"6","author":"Qin","year":"2020","journal-title":"Sci Adv."},{"key":"10.1016\/j.copbio.2023.103045_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202106015","article-title":"Engineering robust Ag-decorated polydopamine nano-photothermal platforms to combat bacterial infection and prompt wound healing","volume":"9","author":"Qi","year":"2022","journal-title":"Adv Sci"},{"key":"10.1016\/j.copbio.2023.103045_bib41","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.apsb.2022.11.003","article-title":"Hollow copper sulfide nanoparticles carrying ISRIB for the sensitized photothermal therapy of breast cancer and brain metastases through inhibiting stress granule formation and reprogramming tumor-associated macrophages","volume":"13","author":"Tong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.copbio.2023.103045_bib42","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.chempr.2019.06.003","article-title":"Calcium-overload-mediated tumor therapy by calcium peroxide nanoparticles","volume":"5","author":"Zhang","year":"2019","journal-title":"Chem"},{"key":"10.1016\/j.copbio.2023.103045_bib43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2217\/nnm.09.75","article-title":"Pharmaceutical stability aspects of nanomedicines","volume":"4","author":"Muthu","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.copbio.2023.103045_bib44","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1039\/c2cs15260f","article-title":"The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy","volume":"41","author":"Doane","year":"2012","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.copbio.2023.103045_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/nl0347334","article-title":"Probing the cytotoxicity of semiconductor quantum dots","volume":"4","author":"Derfus","year":"2004","journal-title":"Nano Lett"},{"key":"10.1016\/j.copbio.2023.103045_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103677","article-title":"Nanomedicine tactics in cancer treatment: challenge and hope","volume":"174","author":"Al-Zoubi","year":"2022","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.copbio.2023.103045_sbref47","article-title":"Safety considerations of cancer nanomedicine\u2014a key step toward translation","volume":"16","author":"Liu","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.copbio.2023.103045_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2023.103045_sbref49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.137147","article-title":"Nanomedicines and nanomaterials for cancer therapy: progress, challenge and perspectives","volume":"446","author":"Jing","year":"2022","journal-title":"Chem Eng J"},{"key":"10.1016\/j.copbio.2023.103045_bib50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nnano.2010.250","article-title":"Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation","volume":"6","author":"Deng","year":"2011","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.copbio.2023.103045_bib51","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.2147\/IJN.S139687","article-title":"Nanomedicinal products: a survey on specific toxicity and side effects","volume":"12","author":"Brand","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.copbio.2023.103045_bib52","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2147\/IJN.S102385","article-title":"A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements","volume":"11","author":"Giannakou","year":"2016","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.copbio.2023.103045_bib53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.copbio.2023.103045_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/nnm.15.196","article-title":"Endotoxin contamination: a key element in the interpretation of nanosafety studies","volume":"11","author":"Li","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.copbio.2023.103045_bib55","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/138161210791208992","article-title":"Nanotechnology and nanomedicine: going small means aiming big","volume":"16","author":"Kumar Teli","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.copbio.2023.103045_bib56","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.drudis.2018.01.047","article-title":"Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities","volume":"23","author":"Agrahari","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.copbio.2023.103045_bib57","first-page":"1005","article-title":"Nanotherapeutics in the EU: an overview on current state and future directions","volume":"9","author":"Hafner","year":"2014","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.copbio.2023.103045_sbref58","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101008","article-title":"Progress, challenges, and future of nanomedicine","volume":"35","author":"Zhang","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.copbio.2023.103045_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: An industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.copbio.2023.103045_bib60","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nmat3792","article-title":"Strategies for advancing cancer nanomedicine","volume":"12","author":"Chauhan","year":"2013","journal-title":"Nat Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-chembioeng-061010-114300","article-title":"Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies","volume":"2","author":"Chauhan","year":"2011","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"10.1016\/j.copbio.2023.103045_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201802227","article-title":"Acid-responsive transferrin dissociation and GLUT mediated exocytosis for increased blood\u2013brain barrier transcytosis and programmed glioma targeting delivery","volume":"28","author":"Ruan","year":"2018","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib63","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1021\/acsnano.7b06969","article-title":"Ferritin nanocarrier traverses the blood brain barrier and kills glioma","volume":"12","author":"Fan","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.copbio.2023.103045_bib64","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1152\/physrev.00037.2011","article-title":"Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer","volume":"92","author":"Wiig","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.copbio.2023.103045_bib65","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.copbio.2023.103045_bib66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2020.08.024","article-title":"Enhancement of tumour penetration by nanomedicines through strategies based on transport processes and barriers","volume":"328","author":"Yang","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.copbio.2023.103045_bib67","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nnano.2013.181","article-title":"Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology","volume":"8","author":"Tenzer","year":"2013","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.copbio.2023.103045_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/nano11040888","article-title":"Hard and soft protein corona of nanomaterials: analysis and relevance","volume":"11","author":"Garc\u00eda-\u00c1lvarez","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.copbio.2023.103045_sbref69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111541","article-title":"Research progress and application opportunities of nanoparticle\u2013protein corona complexes","volume":"139","author":"Huang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.copbio.2023.103045_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101609","article-title":"Morphology-driven protein corona manipulation for preferential delivery of lipid nanodiscs","volume":"46","author":"Chen","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.copbio.2023.103045_bib71","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1021\/acs.nanolett.0c03982","article-title":"Enhanced cancer-targeted drug delivery using precoated nanoparticles","volume":"20","author":"Yu","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.copbio.2023.103045_sbref72","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41565-023-01455-7","article-title":"Cholesterol modulates the physiological response to nanoparticles by changing the composition of protein corona","volume":"18","author":"Tang","year":"2023","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.copbio.2023.103045_bib73","article-title":"The human in vivo biomolecule corona onto PEGylated liposomes: a proof-of-concept clinical study","volume":"31","author":"Hadjidemetriou","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.copbio.2023.103045_bib74","first-page":"401","article-title":"Changes in target ability of nanoparticles due to protein corona composition and disease state","volume":"17","author":"Xu","year":"2022","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.copbio.2023.103045_bib75","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.bioconjchem.8b00743","article-title":"Protein corona formed from different blood plasma proteins affects the colloidal stability of nanoparticles differently","volume":"29","author":"Ho","year":"2018","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.copbio.2023.103045_bib76","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1021\/acsbiomaterials.1c00804","article-title":"Correlating corona composition and cell uptake to identify proteins affecting nanoparticle entry into endothelial cells","volume":"7","author":"Aliyandi","year":"2021","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.copbio.2023.103045_bib77","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1021\/acs.molpharmaceut.1c00525","article-title":"Unraveling the effect of breast cancer patients\u2019 plasma on the targeting ability of folic acid-modified chitosan nanoparticles","volume":"18","author":"Nemati","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.copbio.2023.103045_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120888","article-title":"The protein corona hampers the transcytosis of transferrin-modified nanoparticles through blood\u2013brain barrier and attenuates their targeting ability to brain tumor","volume":"274","author":"Xiao","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.copbio.2023.103045_bib79","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1021\/acs.bioconjchem.0c00240","article-title":"The protein corona does not influence receptor-mediated targeting of virus-like particles","volume":"31","author":"Zackova Suchanova","year":"2020","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.copbio.2023.103045_bib80","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addr.2009.03.009","article-title":"Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.copbio.2023.103045_bib81","doi-asserted-by":"crossref","first-page":"16968","DOI":"10.1073\/pnas.1105270108","article-title":"Binding of blood proteins to carbon nanotubes reduces cytotoxicity","volume":"108","author":"Ge","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.copbio.2023.103045_bib82","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41565-018-0344-3","article-title":"Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles","volume":"14","author":"Vu","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.copbio.2023.103045_bib83","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.119.258012","article-title":"The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses","volume":"370","author":"Moghimi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.copbio.2023.103045_bib84","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2023.103045_bib85","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-14-3280","article-title":"Combined MYC activation and pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer","volume":"76","author":"Hubbard","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.copbio.2023.103045_bib86","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.addr.2014.09.009","article-title":"Lessons from patient-derived xenografts for better in vitro modeling of human cancer","volume":"79\u201380","author":"Choi","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.copbio.2023.103045_bib87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ame2.12165","article-title":"Cancer models in preclinical research: a chronicle review of advancement in effective cancer research","volume":"4","author":"Sajjad","year":"2021","journal-title":"Anim Models Exp Med"},{"key":"10.1016\/j.copbio.2023.103045_bib88","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.copbio.2023.103045_sbref89","article-title":"Organoids technology for advancing the clinical translation of cancer nanomedicine","volume":"15","author":"Zhao","year":"2023","journal-title":"Wiley Inter Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.copbio.2023.103045_bib90","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2018.06.024","article-title":"Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?","volume":"131","author":"M\u00fchlebach","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.copbio.2023.103045_bib91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jin2.34","article-title":"Identification of regulatory needs for nanomedicines","volume":"3","author":"Bremer-Hoffmann","year":"2018","journal-title":"J Interdiscip Nanomed"},{"key":"10.1016\/j.copbio.2023.103045_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120557","article-title":"Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy","volume":"268","author":"Huang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.copbio.2023.103045_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100924","article-title":"Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression","volume":"35","author":"Chen","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.copbio.2023.103045_bib94","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nnano.2012.168","article-title":"Microfluidic technologies for accelerating the clinical translation of nanoparticles","volume":"7","author":"Valencia","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.copbio.2023.103045_bib95","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/acs.jpcb.5b02891","article-title":"Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems","volume":"119","author":"Leung","year":"2015","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.copbio.2023.103045_bib96","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.tibtech.2017.12.001","article-title":"Rational design of mouse models for cancer research","volume":"36","author":"Landgraf","year":"2018","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.copbio.2023.103045_bib97","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.aaw7567","article-title":"Organoids by design","volume":"364","author":"Takebe","year":"2019","journal-title":"Science"}],"container-title":["Current Opinion in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166923001556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166923001556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:20:24Z","timestamp":1760692824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0958166923001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":97,"alternative-id":["S0958166923001556"],"URL":"https:\/\/doi.org\/10.1016\/j.copbio.2023.103045","relation":{},"ISSN":["0958-1669"],"issn-type":[{"value":"0958-1669","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and challenges in the translation of cancer nanomedicines","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.copbio.2023.103045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103045"}}